Primary Cutaneous B-Cell Lymphomas: Recent Advances in Diagnosis and Management
Authors:
Open Access
- 1 July 2012
- journal article
- research article
- Published by SAGE Publications in Cancer Control
- Vol. 19 (3) , 236-244
Abstract
Primary cutaneous B-cell lymphoma (PCBCL) is a heterogeneous group of rare clonal B-cell lymphoproliferative disorders with distinct clinicopathologic features from more common nodal B-cell lymphomas. We performed a systematic review of the relevant literature in the MEDLINE database and analyzed laboratory and clinical data. This review discusses the three most common types of PCBCL: primary cutaneous marginal zone lymphoma (PCMZL), primary cutaneous follicle-center lymphoma (PCFCL), and primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL, LT). Skin biopsies with histology, immunohistochemistry, and molecular clonality studies are essential for a correct diagnosis of cutaneous B-cell lymphoma. Comprehensive lymphoma staging with laboratory and imaging studies and bone marrow aspiration and biopsy are important for determining the prognosis and differentiation of PCBCL from secondary skin involvement with systemic B-cell lymphomas. PCMZL and PCFCL are low-grade PCBCLs, with an estimated 5-year disease-specific survival rate of greater than 95%. Surgical excision or focal radiation therapy is sufficient to control stages T1 and T2 disease. Rituximab monotherapy is frequently used for patients with stage T3 disease. PCDLBCL, LT is an intermediate-grade B-cell lymphoma, with a 5-year disease-specific survival rate of approximately 50%. An anthracycline-based chemotherapy regimen with rituximab is usually required as initial therapy to improve outcomes. In less than a decade, significant progress has been made in our understanding of PCBCL. Novel classification, staging, and prognostic systems have resulted in more accurate diagnosis and prognosis. Although no randomized prospective studies have been conducted in PCBCL, therapies derived from systemic B-cell lymphomas have shown promising results.Keywords
This publication has 38 references indexed in Scilit:
- CLIPI: a new prognostic index for indolent cutaneous B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11)Annals of Hematology, 2010
- European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomasBlood, 2008
- TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC)Blood, 2007
- Reclassification of 300 Primary Cutaneous B-Cell Lymphomas According to the New WHO–EORTC Classification for Cutaneous Lymphomas: Comparison With Previous Classifications and Identification of Prognostic MarkersJournal of Clinical Oncology, 2007
- The Cutaneous B-Cell Lymphoma Prognostic Index: A Novel Prognostic Index Derived From a Population-Based RegistryJournal of Clinical Oncology, 2005
- WHO-EORTC classification for cutaneous lymphomasBlood, 2005
- Multilesional Primary Cutaneous Diffuse Large B-Cell Lymphoma Responsive to Antibiotic TreatmentDermatology, 2001
- Primary Cutaneous B-Cell Lymphoma and Borrelia burgdorferi Infection in Patients From the Highlands of ScotlandAmerican Journal of Surgical Pathology, 2000
- Positive serology for Lyme disease Borrelias in primary cutaneous B-cell lymphoma: a study in 22 patients; is it a fortuitous finding?Hematological Oncology, 1999
- Borrelia burgdorferi—associated cutaneous B cell lymphoma: Clinical and immunohistologic characterization of four casesJournal of the American Academy of Dermatology, 1991